Your browser doesn't support javascript.
loading
First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib.
James, Dominic I; Smith, Kate M; Jordan, Allan M; Fairweather, Emma E; Griffiths, Louise A; Hamilton, Nicola S; Hitchin, James R; Hutton, Colin P; Jones, Stuart; Kelly, Paul; McGonagle, Alison E; Small, Helen; Stowell, Alexandra I J; Tucker, Julie; Waddell, Ian D; Waszkowycz, Bohdan; Ogilvie, Donald J.
Afiliação
  • James DI; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Smith KM; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Jordan AM; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Fairweather EE; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Griffiths LA; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Hamilton NS; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Hitchin JR; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Hutton CP; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Jones S; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Kelly P; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • McGonagle AE; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Small H; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Stowell AI; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Tucker J; Structure and Biophysics, Discovery Sciences, AstraZeneca , Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.
  • Waddell ID; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Waszkowycz B; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
  • Ogilvie DJ; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom.
ACS Chem Biol ; 11(11): 3179-3190, 2016 11 18.
Article em En | MEDLINE | ID: mdl-27689388
The enzyme poly(ADP-ribose) glycohydrolase (PARG) performs a critical role in the repair of DNA single strand breaks (SSBs). However, a detailed understanding of its mechanism of action has been hampered by a lack of credible, cell-active chemical probes. Herein, we demonstrate inhibition of PARG with a small molecule, leading to poly(ADP-ribose) (PAR) chain persistence in intact cells. Moreover, we describe two advanced, and chemically distinct, cell-active tool compounds with convincing on-target pharmacology and selectivity. Using one of these tool compounds, we demonstrate pharmacology consistent with PARG inhibition. Further, while the roles of PARG and poly(ADP-ribose) polymerase (PARP) are closely intertwined, we demonstrate that the pharmacology of a PARG inhibitor differs from that observed with the more thoroughly studied PARP inhibitor olaparib. We believe that these tools will facilitate a wider understanding of this important component of DNA repair and may enable the development of novel therapeutic agents exploiting the critical dependence of tumors on the DNA damage response (DDR).
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Sondas Moleculares / Reparo do DNA / Glicosídeo Hidrolases Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Sondas Moleculares / Reparo do DNA / Glicosídeo Hidrolases Idioma: En Ano de publicação: 2016 Tipo de documento: Article